Kidney and heart involvement

Hepatic response criteria in light chain amyloidosis: a multicenter validation study

Muchtar E, Palladini G, Schonland S, …, Szalat R, …, Gertz MA

HaematologicaDOI: Hepatic response criteria in light chain amyloidosis: a multicenter validation studyPubMed: Hepatic response criteria in light chain amyloidosis: a multicenter validation study

Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency

Cetin O, Staron A, Teodorescu P, Sloan JM, Sanchorawala V, Szalat R

American Journal of Hematology100(12):2416-2420DOI: Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X DeficiencyPubMed: Bleeding Patterns and Clinical Outcomes in Patients With Systemic AL Amyloidosis‐Related Acquired Factor X Deficiency

Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Muchtar E, Wisniowski B, Geyer S, …, Szalat R, …, Gertz MA

JAMA Oncology10(10):1362DOI: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain AmyloidosisPubMed: Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis

Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

Journal of Clinical Oncology41(7):1393-1403DOI: Graded Cardiac Response Criteria for Patients With Systemic Light Chain AmyloidosisPubMed: Graded Cardiac Response Criteria for Patients With Systemic Light Chain Amyloidosis

Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Szalat R, Sarosiek S, Havasi A, Brauneis D, Sloan JM, Sanchorawala V

Leukemia35(3):916-919DOI: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosisPubMed: Organ responses after highdose melphalan and stemcell transplantation in AL amyloidosis

Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Cohen C, Royer B, Javaugue V, Szalat R, …, Bridoux F

Kidney International88(5):1135-1143DOI: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition diseasePubMed: Bortezomib produces high hematological response rates with prolonged renal survival in monoclonal immunoglobulin deposition disease

Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

Harel S, Mohr M, Jahn I, …, Szalat R, …, Fermand J

British Journal of Haematology168(5):671-678DOI: Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 casesPubMed: Clinico‐biological characteristics and treatment of type I monoclonal cryoglobulinaemia: a study of 64 cases

Manifestations cutanées révélant une cryofibrinogénémie associée à une gammapathie monoclonale

Delyon J, Bezier M, Cordoliani F, Malphettes M, Szalat R, Bagot M, Rybojad M

Annales de Dermatologie et de Vénéréologie140(1):30-35DOI: Manifestations cutanées révélant une cryofibrinogénémie associée à une gammapathie monoclonalePubMed: Manifestations cutanées révélant une cryofibrinogénémie associée à une gammapathie monoclonale

Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Cetin O, Teodorescu P, Staron A, Sanchorawala V, Szalat RE

Blood144(Supplement 1):4671-4671DOI: Clinical Characteristics and Treatment Outcomes of Patients with AL Amyloidosis with Acquired Factor X Deficiency

Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

Granina E, Henderson J, Bertrand KA, Sanchorawala V, Szalat RE

Blood144(Supplement 1):4680-4680DOI: Epidemiological Characteristics and Clinical Outcomes of Patients with Monoclonal Gammopathy of Renal Significance (MGRS) Diagnosed in a Large Safety-Net Hospital in the US

Epidemiology and clinical characteristics of patients with monoclonal gammopathy of renal significance (MGRS) in a diverse population

Granina E, Henderson J, Bertrand K, Sanchorawala V, Szalat R

AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS31:S135-S135

Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Muchtar E, Palladini G, Schonland S, …, Szalat RE, …, Gertz MA

Blood142(Supplement 1):3411-3411DOI: Hepatic Response and Progression Criteria in Light Chain Amyloidosis: A Multicenter Validation Study

Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Muchtar E, Dispenzieri A, Wisniowski B, …, Szalat R, …, Gertz MA

Blood138(Supplement 1):2720-2720DOI: Graded Cardiac Response Criteria for AL Amyloidosis: The Impact of Depth of Cardiac Response on Survival

Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz MA

Blood138(Supplement 1):2721-2721DOI: Graded Renal Response Criteria for Light Chain (AL) Amyloidosis

OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis

Muchtar E, Wisniowski B, Palladini G, …, Szalat R, …, Gertz M

Clinical Lymphoma Myeloma and Leukemia21:S23-S24DOI: OAB-036: Graded renal response criteria and revised renal progression criteria for light chain (AL) amyloidosis